Update and new trends in antiemetic therapy and supportive care

37 / 50

THE BENEFIT OF ADDING AN NK1RECEPTOR ANTAGONIST:
EFFICACY BASED ON 13 RANDOMIZED CLINICAL TRIALS INCLUDING 7518 PATIENTS
ABSOLUTE BENEFIT
WITH THE ADDITION OF
NK1RECEPTOR ANTAGONIST
NUMBER NEEDED TO TREAT
(NNT) FOR 1 PATIENT
TO BENEFIT
CISPLATIN:
5 Large Randomized Trials 16% 6
(N = 2723)
CARBOPLATIN:
5 Randomized Trials 14% 7
(N = 1142)
ANTHRACYCLINE + CYCLOPHOSPHAMIDE
3 Large Randomized Trials 12% 8
(N = 3653)
References: Hesketh, J Clin Oncol 2003. Poli-Bigelli, Cancer 2003. Schmoll, Ann Oncol 2006. Rapoport, Lancet Oncol 2015. Hesketh, Ann Oncol 2014. Jordan, Ann Oncol 2015. Gralla, J Clin Oncol 2010.
Tanoika, Br J Cancer 2013. Ito, Lung Cancer 201Yahata, Ann Oncol 2014. Hesketh, J Clin Oncol 2016. Warr, J Clin Oncol 2005. Aapro, Ann Oncol 2014. Schwarzberg, Lancet Oncol 2015.